<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317236</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-BEQ-QTP-002-V.01</org_study_id>
    <nct_id>NCT03317236</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.</brief_title>
  <official_title>Bioequivalence Study of Quetiapine in Healthy Volunteers, After Administering a Single Dose of the Test Extended Release Formulation, Kemoter XR With Respect to the Reference Product, Etiasel XR ® From AstraZeneca S.A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Elea S.A.C.I.F. y A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DominguezLab S.R.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorio Elea S.A.C.I.F. y A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study of quetiapine in healthy volunteers, comparing the test extended release
      formulation, Kemoter XR with respect to the reference product, Etiasel XR ® from AstraZeneca
      S.A., under a single-dose, two-way crossover design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, two-way crossover.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>36 hours</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>36 hours</time_frame>
    <description>Area under curve</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test - Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>A fixed 50 mg exteded release formulation.</description>
    <arm_group_label>Reference - Test</arm_group_label>
    <arm_group_label>Test - Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Healthy volunteers according to medical history, physical exam, clinical laboratory,
             chest X-rays and ECG.

          -  Gender: males and non pregnant females

          -  Age: 18 to 55 years.

          -  Body mass index: 19 to 27 kg/m^2.

        Exclusion Criteria:

          -  History of liver or renal disease, or psychiatric disorders.

          -  History of drug or alcohol abuse during the previous two years.

          -  Smokers of more than 10 cigarrettes a day.

          -  Any kind of medicines taken during the previous two weeks.

          -  Any history of disease or disorders clinically significant according to the Principal
             Investigator.

          -  Abnormal ECG.

          -  Abnormal chest X-ray.

          -  Hypersensitivity to quetiapine or excipients within the formulations.

          -  Positive diagnostic test for HIV or hepatitis A, B or C virus.

          -  Breast feeding females.

          -  Positive beta-HCG test.

          -  Positive drug test in urine.

          -  Participation in clinical trials in the previous three months.

          -  Blood donation in the previous three months.

          -  Clinically significant laboratory results.

          -  Subjects seeking to initiate any medical or pharmacological treatment.

          -  Subjects unwilling to keep fasting or diet indications.

          -  Uncooperative subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María C Fritz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DominguezLab S.R.L.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DominguezLab</name>
      <address>
        <city>Paraná</city>
        <state>Entre Ríos</state>
        <zip>3102</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Quetiapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

